Antibody Drug Treatment for Steroid-Resistant Rejection After Pediatric Living Donor Liver Transplantation: A Single-Center Experience.

•The effectiveness of ATG after pediatric LDLT has not yet been reported.•The median concentration of ALT significantly declined from 193.5 (range, 8–508) to 78 (range, 9–655) mU/mL in the antibody drug group after treatment (P = .012), and the median RAI significantly declined from 5 (range, 2–9) to 1 (range, 0–9) (P = .004).•After antibody drug treatment, 12 patients had CMV infections, 2 patients had EBV infections, 3 patients had respiratory infections, and 1 patient had encephalitis. The cause of death in 1 patient with SRR was recurrence of infant fulminant hepatic failure.•Antibody drug treatment for SRR after pediatric LDLT is safe and effective.